(Q71607382)
Statements
Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T cells (autolymphocyte therapy): results from a pilot study (English)
Ross S
Liu V
Abulafia R
Hogan C
1 January 1993